

# Toshiaki Iba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2516980/publications.pdf>

Version: 2024-02-01

217  
papers

12,940  
citations

44444

50  
h-index

30277

107  
g-index

228  
all docs

228  
docs citations

228  
times ranked

15587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Activation and Thrombosis in COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 055-061.	1.5	17
2	Impact of Extended Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion on Hemodynamics, Vasoactive Substance Requirement, and Pulmonary Oxygenation in Patients with Sepsis: An Observational Study. <i>Blood Purification</i> , 2022, 51, 62-69.	0.9	7
3	Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic. <i>Thrombosis and Haemostasis</i> , 2022, 122, 008-019.	1.8	11
4	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Critical Care Medicine</i> , 2022, 50, e80-e86.	0.4	30
5	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 1-9.	2.3	31
6	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. <i>Minerva Medica</i> , 2022, 112, .	0.3	7
7	Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines. <i>Journal of Intensive Care</i> , 2022, 10, 4.	1.3	0
8	Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. <i>EClinicalMedicine</i> , 2022, 44, 101276.	3.2	21
9	Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 249-256.	2.3	28
10	Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019. <i>Journal of Clinical Medicine</i> , 2022, 11, 985.	1.0	14
11	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
12	Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 6-7.	2.3	9
13	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (JSCG 2020). <i>Acute Medicine &amp; Surgery</i> , 2021, 8, e659.	0.5	37
14	Recent advances in the research and management of sepsis-associated DIC. <i>International Journal of Hematology</i> , 2021, 113, 24-33.	0.7	46
15	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. <i>International Journal of Hematology</i> , 2021, 113, 330-336.	0.7	16
16	Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. <i>Thrombosis Journal</i> , 2021, 19, 12.	0.9	8
17	Thrombosis and Coronavirus Disease 2019: Controversies and (Tentative) Conclusions. <i>Clinical Infectious Diseases</i> , 2021, 73, 2294-2297.	2.9	7
18	Diagnosis of Sepsis by AI-Aided Proteomics Using 2D Electrophoresis Images of Patient Serum Incorporating Transfer Learning for Deep Neural Networks. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1967.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. Expert Review of Respiratory Medicine, 2021, 15, 1003-1011.	1.0	12
20	Endothelial Injury in COVID-19 and Acute Infections. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1774-1776.	1.1	17
21	Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation. Journal of Clinical Medicine, 2021, 10, 2860.	1.0	16
22	Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. Archives of Medical Research, 2021, 52, 788-797.	1.5	32
23	COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. International Journal of Laboratory Hematology, 2021, 43, 29-35.	0.7	37
24	A new SOFA score calculation to improve the predictive performance for mortality in sepsis-associated disseminated intravascular coagulopathy patients. Journal of Critical Care, 2021, 64, 108-113.	1.0	2
25	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG) Tj ETQq1 1 0.784314 rgBT /Over	1.3	92
26	Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal of Clinical Medicine, 2021, 10, 191.	1.0	83
27	COVID-19 coagulopathy: is it disseminated intravascular coagulation?. Internal and Emergency Medicine, 2021, 16, 309-312.	1.0	68
28	Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. International Journal of Molecular Sciences, 2021, 22, 176.	1.8	10
29	Thrombin-Antithrombin System. , 2021, , 43-51.		0
30	Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. Journal of Intensive Care Medicine, 2020, 35, 643-649.	1.3	60
31	Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Seminars in Thrombosis and Hemostasis, 2020, 46, 089-095.	1.5	124
32	The authors reply. Critical Care Medicine, 2020, 48, e989-e990.	0.4	0
33	ISTH DIC subcommittee communication on anticoagulation in COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 2138-2144.	1.9	69
34	The authors reply. Critical Care Medicine, 2020, 48, e1160-e1161.	0.4	7
35	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2400-2407.	1.9	16
36	COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry Communication from the ISTH SSC for Women's Health. Journal of Thrombosis and Haemostasis, 2020, 18, 3086-3098.	1.9	54

#	ARTICLE	IF	CITATIONS
37	The coagulopathy, endotheliopathy, and vasculitis of COVID-19. <i>Inflammation Research</i> , 2020, 69, 1181-1189.	1.6	302
38	Severe Antithrombin Deficiency May be Associated With a High Risk of Pathological Progression of DIC With Suppressed Fibrinolysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094111.	0.7	4
39	Reply to "Errors in the diagnosis for DIC due to a statistical misunderstanding". <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1792-1793.	1.9	3
40	Coagulopathy of Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1358-1364.	0.4	412
41	Coagulation abnormalities and thrombosis in patients with COVID-19. <i>Lancet Haematology</i> , 2020, 7, e438-e440.	2.2	1,186
42	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1859-1865.	1.9	547
43	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter to the Editor by Dr Wada. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1507-1509.	1.9	1
44	Coagulopathy in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2103-2109.	1.9	453
45	The unique characteristics of COVID-19 coagulopathy. <i>Critical Care</i> , 2020, 24, 360.	2.5	366
46	ISTH interim guidance on recognition and management of coagulopathy in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1023-1026.	1.9	1,513
47	Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1618-1625.	1.9	32
48	Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 740-747.	1.9	56
49	The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. <i>Microcirculation</i> , 2020, 27, e12617.	1.0	26
50	Antimicrobial peptide LL-37 ameliorates a murine sepsis model via the induction of microvesicle release from neutrophils. <i>Innate Immunity</i> , 2020, 26, 565-579.	1.1	15
51	Type and dose of heparin in Covid-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2063-2064.	1.9	19
52	DOACs and "newer" hemophilia therapies in COVID-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1795-1796.	1.9	17
53	Laboratory haemostasis monitoring in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2058-2060.	1.9	25
54	Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. <i>Anesthesiology</i> , 2020, 132, 1238-1245.	1.3	99

#	ARTICLE	IF	CITATIONS
55	COVID-19-associated coagulopathy and thrombosis. Japanese Journal of Thrombosis and Hemostasis, 2020, 31, 600-603.	0.1	2
56	Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential. Critical Care, 2019, 23, 280.	2.5	79
57	Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk. Thrombosis Journal, 2019, 17, 12.	0.9	25
58	Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?. Journal of Thrombosis and Haemostasis, 2019, 17, 1973-1978.	1.9	17
59	Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1989-1994.	1.9	325
60	<p>Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 791-802.	0.9	3
61	Glycocalyx damage and microcirculatory disturbance. Japanese Journal of Thrombosis and Hemostasis, 2019, 30, 726-732.	0.1	1
62	Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Critical Care, 2019, 23, 302.	2.5	22
63	Multiple biomarkers of sepsis identified by novel time-lapse proteomics of patient serum. PLoS ONE, 2019, 14, e0222403.	1.1	16
64	Does TeamSTEPPS affect psychological status?. International Journal of Health Care Quality Assurance, 2019, 32, 11-20.	0.2	5
65	The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS. Journal of Intensive Care, 2019, 7, 31.	1.3	15
66	Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Journal of Clinical Medicine, 2019, 8, 728.	1.0	128
67	DIC in obstetrics: Diagnostic score, highlights in management, and international registry—communication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2019, 17, 1562-1566.	1.9	25
68	Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. Journal of Intensive Care, 2019, 7, 32.	1.3	42
69	Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1265-1268.	1.9	37
70	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thrombosis Research, 2019, 179, 11-14.	0.8	41
71	Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961882404.	0.7	24
72	Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy. Acute Medicine & Surgery, 2019, 6, 223-232.	0.5	63

#	ARTICLE	IF	CITATIONS
73	Predicting mortality in patients with disseminated intravascular coagulation after cardiopulmonary bypass surgery by utilizing two scoring systems. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 11-16.	0.5	6
74	Derangement of the endothelial glycocalyx in sepsis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 283-294.	1.9	196
75	Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 415-419.	1.9	50
76	Oh, how hard it is to open the gate for sepsis trials: lessons from <sc>SCARLET</sc>. <i>Acute Medicine &amp; Surgery</i> , 2019, 6, 3-4.	0.5	5
77	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J&sc>SSCG</sc> 2016). <i>Acute Medicine &amp; Surgery</i> , 2018, 5, 3-89.	0.5	61
78	Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage. <i>International Journal of Hematology</i> , 2018, 107, 528-534.	0.7	9
79	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). <i>Journal of Intensive Care</i> , 2018, 6, 7.	1.3	74
80	Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1020-1026.	0.7	32
81	A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 439-445.	0.7	40
82	Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 231-241.	1.9	333
83	Role of extracellular vesicles in the development of sepsis-induced coagulopathy. <i>Journal of Intensive Care</i> , 2018, 6, 68.	1.3	52
84	Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis. <i>Thrombosis Research</i> , 2018, 171, 1-6.	0.8	39
85	Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 145S-149S.	0.7	11
86	Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. <i>Thrombosis Journal</i> , 2018, 16, 14.	0.9	75
87	A re&sc>evaluation of the D&sc>dimer cut&sc>off value for making a diagnosis according to the ISTH overt&sc>DIC diagnostic criteria: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1442-1444.	1.9	48
88	Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation: A Third Survey. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 422-428.	0.7	14
89	Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 677-684.	0.7	13
90	Neutrophil extracellular traps induce IL-1 <sup>2</sup> production by macrophages in combination with lipopolysaccharide. <i>International Journal of Molecular Medicine</i> , 2017, 39, 549-558.	1.8	48

#	ARTICLE	IF	CITATIONS
91	The application of anticoagulant therapy to sepsis. <i>Journal of Intensive Care</i> , 2017, 5, 32.	1.3	5
92	Evaluation of the effect of recombinant thrombomodulin on a lipopolysaccharide-induced murine sepsis model. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 2969-2974.	0.8	17
93	New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. <i>BMJ Open</i> , 2017, 7, e017046.	0.8	230
94	Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation. <i>Annals of Intensive Care</i> , 2017, 7, 110.	2.2	22
95	Is protein C zymogen really ineffective for ALL cases of sepsis including septic DIC?. <i>Intensive Care Medicine</i> , 2017, 43, 152-153.	3.9	0
96	Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. <i>Journal of Intensive Care</i> , 2017, 5, 40.	1.3	25
97	Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis. <i>Journal of Intensive Care</i> , 2017, 5, 56.	1.3	16
98	Antimicrobial cathelicidin peptide LL-37 induces NET formation and suppresses the inflammatory response in a mouse septic model. <i>Molecular Medicine Reports</i> , 2017, 16, 5618-5626.	1.1	31
99	The Comparison of the Protective Effects of $\hat{1}\pm$ - and $\hat{1}^2$ -Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro. <i>TH Open</i> , 2017, 01, e3-e10.	0.7	4
100	Glycocalyx Regulates the Intravascular Hemostasis. <i>Juntendo Medical Journal</i> , 2016, 62, 330-335.	0.1	4
101	Physiological Levels of Pentraxin 3 and Albumin Attenuate Vascular Endothelial Cell Damage Induced by Histone H3 <i>in Vitro</i> . <i>Microcirculation</i> , 2016, 23, 240-247.	1.0	9
102	Bleeding complications of anticoagulant therapy in sepsis-induced disseminated intravascular coagulation. <i>Critical Care</i> , 2016, 20, 307.	2.5	0
103	Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective?. <i>Intensive Care Medicine</i> , 2016, 42, 1193-1194.	3.9	4
104	Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2016, 145, 46-50.	0.8	16
105	Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. <i>Critical Care</i> , 2016, 20, 287.	2.5	51
106	Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect. <i>International Journal of Hematology</i> , 2016, 103, 665-672.	0.7	6
107	DAMP and DIC: The role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. <i>Blood Reviews</i> , 2016, 30, 257-261.	2.8	139
108	Human Host Defense Cathelicidin Peptide LL-37 Enhances the Lipopolysaccharide Uptake by Liver Sinusoidal Endothelial Cells without Cell Activation. <i>Journal of Immunology</i> , 2016, 196, 1338-1347.	0.4	30

#	ARTICLE	IF	CITATIONS
109	Antimicrobial cathelicidin peptide LL-37 inhibits the pyroptosis of macrophages and improves the survival of polybacterial septic mice. <i>International Immunology</i> , 2016, 28, 245-253.	1.8	56
110	Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. <i>International Journal of Hematology</i> , 2016, 103, 253-261.	0.7	53
111	Potential diagnostic markers for disseminated intravascular coagulation of sepsis. <i>Blood Reviews</i> , 2016, 30, 149-155.	2.8	41
112	Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 453-458.	0.7	6
113	Glycocalyx regulates the intravascular hemostasis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2016, 27, 444-449.	0.1	1
114	Antithrombin or thrombomodulin administration in severe pneumonia patients with sepsis and disseminated intravascular coagulation: comment on two papers. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 682-683.	1.9	3
115	Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. <i>Intensive Care Medicine Experimental</i> , 2015, 3, 36.	0.9	71
116	Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation. <i>Critical Care</i> , 2015, 19, 233.	2.5	0
117	Kinetics of Circulating Damage-Associated Molecular Patterns in Sepsis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	0.9	5
118	The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2015, 135, 897-901.	0.8	27
119	The effect of plasma-derived activated protein C on leukocyte cell-death and vascular endothelial damage. <i>Thrombosis Research</i> , 2015, 135, 963-969.	0.8	6
120	The effect of recombinant thrombomodulin on disseminated intravascular coagulation associated with acute pancreatitis. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2015, 22, 402-403.	0.0	0
121	Clinical Elective Study Report at the Department of Emergency and Critical Care Medicine in Juntendo University Faculty of Medicine. <i>Juntendo Medical Journal</i> , 2015, 61, 166-170.	0.1	0
122	Controversies regarding the use of antithrombin for sepsis-associated disseminated intravascular coagulation: an update of the evidence. <i>Blood Transfusion</i> , 2015, 13, 166.	0.3	1
123	Effect of Hemoperfusion Using Polymyxin B-immobilized Fibers on Acute Lung Injury in a Rat Sepsis Model. <i>International Journal of Medical Sciences</i> , 2014, 11, 255-261.	1.1	12
124	Analysis of non-traumatic truncal back pain in patients who visited an emergency room. <i>Acute Medicine &amp; Surgery</i> , 2014, 1, 94-100.	0.5	4
125	A case of paraparesis with thoracic ossification of the posterior longitudinal ligament and the ligamentum flavum induced by falling down on the abdomen. <i>Acute Medicine &amp; Surgery</i> , 2014, 1, 54-57.	0.5	2
126	Is the neutrophil a "prima donna"™ in the procoagulant process during sepsis?. <i>Critical Care</i> , 2014, 18, 230.	2.5	46



#	ARTICLE	IF	CITATIONS
127	Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. <i>Critical Care</i> , 2014, 18, 497.	2.5	50
128	Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation. <i>Journal of Intensive Care</i> , 2014, 2, 66.	1.3	34
129	Combination of antithrombin and recombinant thrombomodulin attenuates leukocyte-endothelial interaction and suppresses the increase of intrinsic damage-associated molecular patterns in endotoxemic rats. <i>Journal of Surgical Research</i> , 2014, 187, 581-586.	0.8	20
130	Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1010-1019.	1.9	69
131	Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. <i>Thrombosis Research</i> , 2014, 133, 276-280.	0.8	19
132	Neutrophil extracellular traps, damage-associated molecular patterns, and cell death during sepsis. <i>Acute Medicine &amp; Surgery</i> , 2014, 1, 2-9.	0.5	11
133	Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". <i>Thrombosis Research</i> , 2014, 134, 924-925.	0.8	29
134	Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats. <i>Thrombosis Research</i> , 2014, 134, 169-173.	0.8	24
135	Is Postoperative Polymyxin B Hemoperfusion for Abdominal Septic Shock Really Ineffective?. <i>Critical Care Medicine</i> , 2014, 42, e596-e597.	0.4	2
136	The Obstacles That Should be Overcome to Develop New Anticoagulants for Severe Sepsis. <i>Critical Care Medicine</i> , 2014, 42, e248-e249.	0.4	1
137	Antimicrobial Cathelicidin Peptide LL-37 Inhibits the LPS/ATP-Induced Pyroptosis of Macrophages by Dual Mechanism. <i>PLoS ONE</i> , 2014, 9, e85765.	1.1	99
138	Disaster Medicine Education and Training for Medical Student at Juntendo University. <i>Juntendo Medical Journal</i> , 2014, 60, 112-118.	0.1	0
139	New therapeutic options for patients with sepsis and disseminated intravascular coagulation. <i>Polish Archives of Internal Medicine</i> , 2014, 124, 321-328.	0.3	7
140	Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. <i>Thrombosis Research</i> , 2013, 131, 295-299.	0.8	20
141	A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. <i>Critical Care</i> , 2013, 17, R297.	2.5	132
142	The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2013, 131, 383-389.	0.8	41
143	Factor X Inhibitor Attenuates Leukocyte Adhesion and Thrombus Formation in an Experimental Mouse Model of the Metabolic Syndrome. <i>Cardiovascular Therapeutics</i> , 2013, 31, 280-284.	1.1	8
144	Neutrophil cell death in response to infection and its relation to coagulation. <i>Journal of Intensive Care</i> , 2013, 1, 13.	1.3	73

#	ARTICLE	IF	CITATIONS
145	Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2076-2078.	1.9	6
146	A Randomized, Controlled, Multicenter Trial of the Effects of Antithrombin on Disseminated Intravascular Coagulation in Patients With Sepsis. <i>Chest</i> , 2013, 144, 418A.	0.4	0
147	A Case of Lung Lesions Induced by a soccer Ball. <i>Clinical Medicine Insights: Trauma and Intensive Medicine</i> , 2013, 4, CMTIM.S11818.	0.2	0
148	Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. <i>Journal of Trauma</i> , 2012, 72, 177-182.	2.3	19
149	The meanings of DIC diagnostic criteria. <i>Thrombosis Research</i> , 2012, 129, e269-e270.	0.8	4
150	Formation of the venous thrombus after venous occlusion in the experimental mouse model of metabolic syndrome. <i>Thrombosis Research</i> , 2012, 129, e246-e250.	0.8	6
151	A case of cardiac arrest with ST elevation induced by contrast medium. <i>American Journal of Emergency Medicine</i> , 2012, 30, 2083.e3-2083.e4.	0.7	7
152	Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey. <i>Thrombosis Research</i> , 2012, 130, e129-e133.	0.8	63
153	Effect of Hemoperfusion Using Polymyxin B-Immobilized Fibers on Non-Shock Rat Sepsis Model. <i>Journal of Surgical Research</i> , 2011, 171, 755-761.	0.8	22
154	Conceptual change of the septic disseminated intravascular coagulation and the progress in its treatment. <i>Nihon Kyukyu Igakukai Zasshi</i> , 2011, 22, 37-45.	0.0	0
155	Comparison between British and Japanese guidelines for the diagnosis and treatment of disseminated intravascular coagulation. <i>British Journal of Haematology</i> , 2010, 149, 461-462.	1.2	8
156	Expert consensus for the treatment of disseminated intravascular coagulation in Japan. <i>Thrombosis Research</i> , 2010, 125, 6-11.	0.8	222
157	Frequency and hemostatic abnormalities in pre-DIC patients. <i>Thrombosis Research</i> , 2010, 126, 74-78.	0.8	26
158	The Current Status of Sepsis Research in Japan in Comparison to the Status of International Research. <i>Juntendol., Igaku</i> , 2010, 56, 334-338.	0.1	0
159	Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. <i>Critical Care</i> , 2009, 13, R203.	2.5	53
160	Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis. <i>Thrombosis Research</i> , 2009, 123, 715-718.	0.8	70
161	ENOXAPARIN ATTENUATES ENDOTHELIAL DAMAGE WITH LESS BLEEDING COMPARED WITH UNFRACTIONATED HEPARIN IN ENDOTOXEMIC RATS. <i>Shock</i> , 2009, 32, 530-534.	1.0	18
162	The current status of the therapeutic approach for severe sepsis in Japan and its comparison to the international guidelines. <i>Nihon Kyukyu Igakukai Zasshi</i> , 2009, 20, 915-922.	0.0	2

#	ARTICLE	IF	CITATIONS
163	Expression of hypoxia-inducible factor 1 $\alpha$ gene affects the outcome in patients with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 499-505.	1.2	41
164	Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1099-1105.	1.8	51
165	Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. <i>Critical Care</i> , 2008, 12, R86.	2.5	21
166	Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey*. <i>Critical Care Medicine</i> , 2008, 36, 145-150.	0.4	205
167	Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1099-1105.	1.8	31
168	SIRS-ASSOCIATED COAGULOPATHY AND ORGAN DYSFUNCTION IN CRITICALLY ILL PATIENTS WITH THROMBOCYTOPENIA. <i>Shock</i> , 2007, 28, 411-417.	1.0	63
169	Predicting the Severity of Systemic Inflammatory Response Syndrome (SIRS)-Associated Coagulopathy With Hemostatic Molecular Markers and Vascular Endothelial Injury Markers. <i>Journal of Trauma</i> , 2007, 63, 1093-1098.	2.3	43
170	Evaluation of haemostatic molecular markers for diagnosis of disseminated intravascular coagulation in patients with infections. <i>Thrombosis and Haemostasis</i> , 2006, 95, 282-287.	1.8	40
171	COMPARISON OF THE PROTECTIVE EFFECTS OF TYPE III PHOSPHODIESTERASE (PDE3) INHIBITOR (CILOSTAZOL) AND ACETYLSALICYLIC ACID ON INTESTINAL MICROCIRCULATION AFTER ISCHEMIA REPERFUSION INJURY IN MICE. <i>Shock</i> , 2006, 26, 522-526.	1.0	47
172	COMPARISON OF THE PROTECTIVE EFFECTS OF CILOSTAZOL AND ACETYLSALICYLIC ACID ON INTESTINAL MICROCIRCULATION AFTER ISCHEMIA REPERFUSION INJURY. <i>Shock</i> , 2006, 25, 38.	1.0	0
173	A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria*. <i>Critical Care Medicine</i> , 2006, 34, 625-631.	0.4	512
174	PRETREATMENT OF SIVELESTAT SODIUM HYDRATE IMPROVES THE LUNG MICROCIRCULATION AND ALVEOLAR DAMAGE IN LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INFLAMMATION IN HAMSTERS. <i>Shock</i> , 2006, 26, 95-98.	1.0	35
175	Physiological protease inhibitors. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2006, 17, 314-319.	0.1	0
176	ASSOCIATION BETWEEN THE SEVERITY OF SEPSIS AND THE CHANGES IN HEMOSTATIC MOLECULAR MARKERS AND VASCULAR ENDOTHELIAL DAMAGE MARKERS. <i>Shock</i> , 2005, 23, 25-29.	1.0	61
177	Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. <i>Critical Care Medicine</i> , 2005, 33, 368-372.	0.4	611
178	Laparoscopy-Assisted Low Anterior Resection with a Prolapsing Technique for Low Rectal Cancer. <i>Surgery Today</i> , 2005, 35, 598-602.	0.7	34
179	Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. <i>Intensive Care Medicine</i> , 2005, 31, 1101-1108.	3.9	22
180	Evaluation of New Japanese Diagnostic Criteria for Disseminated Intravascular Coagulation in Critically Ill Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 71-76.	0.7	77

#	ARTICLE	IF	CITATIONS
181	Activated protein C suppresses the production of pro-inflammatory cytokines and the leukocyte-endothelial interaction in rat LPS model. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2005, 12, 191-195.	0.0	1
182	Laparoscopic Surgery for Left Paraduodenal Hernia. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2004, 14, 111-115.	0.5	37
183	Stromal invasion of the cervix can be excluded from the criteria for using adjuvant radiotherapy following radical surgery for patients with cervical cancer. <i>Gynecologic Oncology</i> , 2004, 93, 628-631.	0.6	19
184	The efficacy of long-term oral chemotherapy with 5?-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer. <i>International Journal of Clinical Oncology</i> , 2004, 9, 383-387.	1.0	3
185	WHAT CAN WE LEARN FROM THE THREE MEGATRIALS USING ANTICOAGULANTS IN SEVERE SEPSIS?. <i>Shock</i> , 2004, 22, 508-512.	1.0	7
186	Title is missing!. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2004, 11, 193-199.	0.0	2
187	Antithrombin Modulates the Leukocyte-Endothelial Cell Interaction in the Staphylococcal Enterotoxin B-Challenged Mouse. <i>Journal of Trauma</i> , 2003, 55, 546-550.	2.3	11
188	Factor Xa-Inhibitor (Dx-9065a) Modulates the Leukocyte-Endothelial Cell Interaction in Endotoxemic Rat. <i>Shock</i> , 2002, 17, 159-162.	1.0	31
189	High-Dose Antithrombin Therapy for Sepsis: Mechanisms of Action. <i>Shock</i> , 2002, 18, 389-394.	1.0	28
190	Title is missing!. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2001, 12, 32-38.	0.1	2
191	A case of Juvenile polyposis localized in the stomach accompanied by anemia and hypoproteinemia. <i>Progress of Digestive Endoscopy</i> , 2001, 59, 52-55.	0.0	3
192	High-Dose Antithrombin Therapy for Sepsis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 49, 979-980.	1.1	5
193	The Unbalance of Coagulation/Fibrinolysis and Microcirculatory Disturbance in Sepsis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2000, 11, 229-235.	0.1	0
194	Role of DIC in multiple organ failure. <i>International Journal of Surgical Investigation</i> , 2000, 2, 73-80.	0.0	5
195	EFFECTS OF ANTITHROMBIN ON VASOACTIVE SUBSTANCES PRODUCTION IN ENDOTOXEMIC RATS.. <i>Shock</i> , 1999, 12, 38.	1.0	0
196	The role of the endothelium in changes in procoagulant activity in sepsis. <i>Journal of the American College of Surgeons</i> , 1998, 187, 321-329.	0.2	58
197	Improvement in Sinusoidal Circulation with Supplement of Antithrombin III in Endotoxemic Rats.. <i>Nihon Kyukyu Igakukai Zasshi</i> , 1998, 9, 579-586.	0.0	0
198	Changes in protein C activity in severe sepsis.. <i>Nihon Kyukyu Igakukai Zasshi</i> , 1998, 9, 294-300.	0.0	0

#	ARTICLE	IF	CITATIONS
199	Protective effects of antithrombin III on organ dysfunction induced by the continuous infusion of endotoxin in rats.. Nihon Kyukyu Igakukai Zasshi, 1998, 9, 45-52.	0.0	3
200	Evaluation of a rat model for disseminated intravascular coagulation developed by infusion of lipopolysaccharide.. Nihon Kyukyu Igakukai Zasshi, 1997, 8, 103-110.	0.0	0
201	Alterations in circulating levels of soluble intercellular adhesion molecule-1 in sepsis.. Nihon Kyukyu Igakukai Zasshi, 1997, 8, 161-167.	0.0	0
202	Changes in Circulating Levels of Tissue Factor and Tissue Factor Pathway Inhibitor in SIRS, Septic MODS and Septic DIC.. Nihon Kyukyu Igakukai Zasshi, 1997, 8, 650-658.	0.0	0
203	Effects of total parenteral nutrition(TPN) supplemented with medium-chain triglyceride(MCT) in rats with endotoxin-induced sepsis.. Nihon Kyukyu Igakukai Zasshi, 1997, 8, 288-296.	0.0	0
204	ALTERATIONS IN COAGULATION AND FIBRINOLYSIS DURING SEPSIS. Shock, 1996, 5, 223-228.	1.0	89
205	Biochemical modulation for 5 -FU No. 1. Juntendo, Igaku, 1996, 41, 492-499.	0.1	0
206	Biochemical modulation for 5 -FU No. 2. Juntendo, Igaku, 1996, 42, 113-120.	0.1	1
207	Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure. Surgery Today, 1995, 25, 585-590.	0.7	62
208	Imbalance between coagulation and fibrinolysis in sepsis.. Nihon Kyukyu Igakukai Zasshi, 1995, 6, 25-32.	0.0	0
209	Changes in plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in sepsis with organ failure.. Nihon Kyukyu Igakukai Zasshi, 1994, 5, 365-372.	0.0	0
210	The significance of humoral mediators in gram-positive infection.. Nihon Kyukyu Igakukai Zasshi, 1993, 4, 291-298.	0.0	0
211	Intracellular cyclic AMP levels in endothelial cells subjected to cyclic strain in vitro. Journal of Surgical Research, 1992, 52, 625-630.	0.8	20
212	Tissue Plasminogen Activator Expression in Endothelial Cells Exposed to Cyclic Strain in Vitro. Cell Transplantation, 1992, 1, 43-50.	1.2	60
213	Stimulation of endothelial secretion of tissue-type plasminogen activator by repetitive stretch. Journal of Surgical Research, 1991, 50, 457-460.	0.8	73
214	Morphological response of human endothelial cells subjected to cyclic strain in vitro. Microvascular Research, 1991, 42, 245-254.	1.1	188
215	Effect of cyclic stretch on endothelial cells from different vascular beds. Circulatory Shock, 1991, 35, 193-8.	0.6	18
216	Modulation of endothelial cell phenotype by cyclic stretch: Inhibition of collagen production. Journal of Surgical Research, 1990, 48, 415-420.	0.8	65

#	ARTICLE	IF	CITATIONS
217	A CASE REPORT OF SPINDLE CELL CARCINOMA IN BILATERAL SYNCHRONOUS BREAST CANCER. The Journal of the Japanese Practical Surgeon Society, 1989, 50, 1149-1154.	0.0	0